Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00046189 · ClinicalTrials.gov registry record

Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
301
Enrollment target

NCT00046189: Completed study, sponsored by National Cancer Institute (NCI).

NCT00046189 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 301 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00046189 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
301 participants
Enrollment target

Study Summary

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers. Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease. XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects. Patients and their family members will undergo some or all of the following procedures: * Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses * Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations * Photographs to document skin and other physical findings * Nuclear medicine scans to evaluate the brain and nervous system * X-rays of the skull or other parts of the body * Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement * Collection of blood and skin samples for gene studies * Establishment of cell lines from collected blood or tissues to study DNA repair,

Trial Details

FieldValue
Enrollment Target 301 participants
Start Date 2003-04-07
Est. Completion 2024-01-05

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00046189

The ClinicalTrials.gov registry entry for NCT00046189 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00046189 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00046189 about?

NCT00046189 is a clinical study titled "Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum". This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an...

What is the current status of trial NCT00046189?

This trial is currently completed. The enrollment target is 301 participants. The study started on 2003-04-07. Estimated completion is 2024-01-05.

Who is sponsoring clinical trial NCT00046189?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.